01.06.2012 • NewsAir LiquideBayerTony Van Osselaer

Air Liquide builds new H2 and CO production plant for Bayer MaterialScience

Air Liquide will invest around €100 million in a production unit to provide Bayer MaterialScience (BMS) with large quantities of hydrogen and carbon monoxide. The French supplier of industrial gases has signed a long-term contract with BMS. The state-of-the-art unit will be designed and built on the Chempark Dormagen site by Air Liquide Global E&C Solutions teams and is scheduled for commissioning in 2014.

The gases will be used for the manufacture of polyurethanes. Bayer MaterialScience is among the world's largest polymer companies. The Bayer Group has been a global customer of Air Liquide for many years, with contracts in 8 countries.

Guy Salzgeber, Vice-President North and Central Europe and a member of the Air Liquide Executive Committee, commented: "We are very pleased with this new long term agreement in Germany with the Bayer Group. This major investment is another important milestone in the long-standing business relationship that has developed between our two companies worldwide. This new production unit will provide us with the opportunity to reinforce our positioning in this dynamic industrial basin, particularly in the chemical and oil and gas industry. Germany is one of the key pillars of the Group in Europe with close to €300million invested in new industrial production units over the last 3 years."

Tony Van Osselaer, Member of the Board of Management of Bayer MaterialScience, Head of Industrial Operations, stated: "This investment by Air Liquide represents an important cornerstone to securing raw materials for our investment in a world-scale TDI unit in Dormagen. With its state of the art technology, we are pleased to haveAir Liquide as a partner."

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.